Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.62% | -21.70% | 20.85% | -280.27% | -93.72% |
| Total Depreciation and Amortization | -51.72% | -97.24% | 208.82% | -508.47% | -86.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.59% | 231.55% | -140.69% | 18.62% | -80.03% |
| Change in Net Operating Assets | 193.10% | 61.80% | 74.94% | 38.32% | 84.45% |
| Cash from Operations | -8.62% | 46.06% | 41.79% | -33.74% | 73.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 1,161.36% | -87.39% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 419.88% | 54.51% | -131.51% |
| Cash from Investing | -- | -- | 448.62% | 52.25% | -129.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 63.50% | -80.11% | 884.08% | 150,700.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -3,119.74% | -103.01% | -- |
| Cash from Financing | 63.50% | 98,466.67% | -100.29% | -93.16% | 6,221.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4,112.30% | -104.45% | 124.55% | -482.75% | 126.06% |